Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
Claims What is claimed is: 1. A compound comprising a modified oligomeric compound, wherein the modified oligomeric compound is 10 to 30 nucleobases in length, specifically hybridizable with SEQ ID NO: 4, and 100% complementary to at least an 8 nucleobase portion of nucleotides 1100 to 1170 of SEQ ID NO: 4 encoding SGLT2, and wherein said modified oligomeric compound comprises: a gap segment consisting of linked deoxynucleosides; a 5' wing segment consisting of linked nucleosides; and a 3' wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each of said nucleosides of each of said wing segments comprises a modified sugar. 2. The compound of claim 1 wherein said modified oligomeric compound comprises 13 to 30 nucleobases in length. 3. The compound of claim 2 wherein said modified oligomeric compound comprises 15 to 25 nucleobases in length. 4. The compound of claim 3 wherein said modified oligomeric compound comprises 18 to 22 nucleobases in length. 5. The compound of claim 1, wherein at least a portion of the modified oligomeric compound hybridizes with RNA to form an oligonucleotide-RNA duplex. 6. The compound of claim 1 wherein said modified oligomeric compound comprises at least 80% complementarity with the nucleic acid molecule encoding SEQ ID NO: 4. 7. The compound of claim 1 wherein said modified oligomeric compound comprises at least 90% complementarity with the nucleic acid molecule encoding SEQ ID NO: 4. 8. The compound of claim 1 wherein said modified oligomeric compound comprises at least 95% complementarity with the nucleic acid molecule encoding SEQ ID NO: 4. 9. The compound of claim 1 wherein said modified oligomeric compound comprises at least 99% complementarity with the nucleic acid molecule encoding SEQ ID NO: 4. 10. The compound of claim 1 wherein said modified oligomeric compound is 100% complementary with the nucleic acid molecule encoding SEQ ID NO: 4. 11. The compound of claim 1 wherein said modified oligomeric compound comprises at least one modified internucleoside linkage, or nucleobase. 12. The compound of claim 11, wherein the modified oligomeric compound comprises at least one modified internucleoside linkage. 13. The compound of claim 11, wherein the modified oligomeric compound comprises at least one modified nucleobase. 14. The compound of claim 1 wherein said modified oligomeric compound comprises at least one 2'-O-methoxyethyl sugar moiety. 15. The compound of claim 1 wherein said modified oligomeric compound comprises at least one phosphorothioate internucleoside linkage. 16. The compound of claim 1 wherein said modified oligomeric compound comprises at least one 5-methylcytosine. 17. The compound of claim 1 wherein the modified oligomeric compound comprises at least an 8-nucleobase portion of SEQ ID NO: 54, 55, or 56. 18. The compound of claim 17 wherein the modified oligomeric compound comprises the nucleobase sequences set forth in SEQ ID NO: 54, 55, or 56. 19. The compound of claim 18, wherein the modified oligomeric compound comprises the nucleobase sequence of SEQ ID NO:54. 20. The compound of claim 18, wherein the modified oligomeric compound comprises the nucleobase sequence of SEQ ID NO:55. 21. The compound of claim 18, wherein the modified oligomeric compound comprises the nucleobase sequence of SEQ ID NO:56. 22. The compound of claim 17, wherein the modified oligomeric compound comprises at least an 8-nucleobase portion of SEQ ID NO:54. 23. The compound of claim 17, wherein the modified oligomeric compound comprises at least an 8-nucleobase portion of SEQ ID NO:55. 24. The compound of claim 17, wherein the modified oligomeric compound comprises at least an 8-nucleobase portion of SEQ ID NO:56. 25. The compound of claim 1 which comprises a first region consisting of at least 5 contiguous 2'-deoxy nucleosides flanked by a second region and a third region, wherein each of the second and third regions, independently, comprises at least one 2'-O-methoxyethyl nucleoside, and wherein the internucleoside linkages of the first region are phosphorothioate linkages and the internucleoside linkages of the second and third regions are phosphodiester linkages. 26. The compound of claim 1, wherein the compound inhibits the expression of SGLT2 mRNA by at least 30%. 27. A method of inhibiting the expression of SGLT2 in a cell or tissue comprising contacting the cell or tissue with the compound of claim 1 so that expression of SGLT2 is inhibited. 28. A kit or assay device comprising the compound of claim 1. 29. A method of treating an animal having a disease or condition associated with SGLT2 comprising administering to the animal a therapeutically effective amount of the compound of claim 1 so that expression of SGLT2 is inhibited. 30. The method of claim 29 wherein the disease or condition is a hyperproliferative or metabolic disorder. 31. A method of inhibiting the expression of SGLT2 in a kidney cell or kidney tissue comprising contacting the kidney cell or kidney tissue with the compound of claim 25. 32. A method of inhibiting expression of SGLT2 in a kidney cell or kidney tissue comprising contacting the kidney cell or kidney tissue with the compound of claim 25 so that expression of SGLT2 is inhibited. 33. The method of claim 32 wherein the compound comprises SEQ ID NO: 54, 55, or 56. 34. A method of delaying the onset of a disease or condition in an animal comprising administering to the animal an effective amount of the compound of claim 25 so that expression of SGLT2 is inhibited, wherein the disease or condition is associated with expression of SGLT2 in the kidney. 35. The method of claim 34 wherein the compound comprises SEQ ID NO: 54, 55, or 56. 36. The method of claim 34 wherein said animal is a human. 37. The method of claim 34 wherein the compound consists of SEQ ID NO: 54, 55, or 56. 38. A method of delaying the onset of type 2 diabetes in an animal comprising administering to the animal the compound of claim 25 so that expression of SGLT2 is inhibited. 39. A method of delaying the onset of an increase in blood glucose level in an animal comprising administering to the animal the compound of claim 25 so that expression of SGLT2 is inhibited. 40. The method of claim 39 wherein the animal is a human. 41. The method of claim 39 wherein the blood glucose level is plasma glucose level or serum glucose level. 42. The method of claim 39 wherein the animal is a diabetic animal. 43. The method of claim 39 wherein the animal is insulin-resistant as compared to a normal animal. 44. The method of claim 39 wherein the compound comprises SEQ ID NO: 54, 55, or 56. 45. A method of decreasing blood glucose level in an animal comprising administering to the animal the compound of claim 25 so that expression of SGLT2 is inhibited. 46. The method of claim 45 wherein the animal is a human. 47. The method of claim 45 wherein the blood glucose level is plasma glucose level or serum glucose level. 48. The method of claim 45 wherein the animal is a diabetic animal. 49. The method of claim 45 wherein the animal is insulin-resistant as compared to a normal animal. 50. The method of claim 45 wherein the compound comprises SEQ ID NO: 54, 55, or 56. 51. A method of inhibiting expression of SGLT2 in a kidney cell or kidney tissue comprising contacting the cell or tissue with the compound of claim 1, wherein the expression of SGLT2 is inhibited. 52. A pharmaceutical composition comprising a modified oligomeric compound, or salt form thereof, wherein the oligomeric compound is 10 to 30 nucleobases in length, specifically hybridizable with SEQ ID NO:4, and 100% complementary to at least an 8 nucleobase portion of nucleotides 1100 to 1170 of SEQ ID NO:4, wherein the oligomeric compound comprises: a gap segment consisting of linked deoxynucleosides; a 5' wing segment consisting of linked nucleosides; and a 3' wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each of said nucleosides of each of said wing segments comprises a modified sugar; and a pharmaceutically acceptable carrier or diluent. 53. The pharmaceutical composition of claim 52, wherein the oligomeric compound comprises: a gap segment consisting of ten linked deoxynucleosides; a 5' wing segment consisting of five linked nucleosides; and a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each of said nucleosides of each of said wing segments comprises a 2'-O-methyoxyethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage. 54. A compound comprising a modified oligomeric compound, wherein the modified oligomeric compound is 10 to 30 nucleobases in length, specifically hybridizable with SEQ ID NO: 4, and 100% complementary to at least an 8 nucleobase portion of nucleotides 1122 to 1141 of SEQ ID NO: 4 encoding SGLT2, and wherein said modified oligomeric compound comprises: a gap segment consisting of linked deoxynucleosides; a 5' wing segment consisting of linked nucleosides; and a 3' wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage. 